Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New magnesium membrane could boost dental implant success

NCT ID NCT06059898

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested a new magnesium membrane (NOVAMag) against a standard collagen membrane (Jason) for rebuilding jawbone in 106 people needing dental implants. The goal was to see if the magnesium membrane is as good at promoting bone growth. Researchers measured bone volume with X-rays and biopsies after six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bioresorbable magnesium membrane (NOVAMag)
What this could lead to
If successful, this could offer a stronger, fully resorbable option for rebuilding jawbone, potentially improving dental implant success.
What could go wrong
This is a completed early-stage comparison, not a large-scale trial. The magnesium membrane may not prove better than the existing collagen option, and individual healing varies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

106 people

The number who actually took part.

Started

Apr 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligible are healthy patients that have the need for at least one dental implant. Specific inclusion criteria are: Inclusion Criteria: 1. Obtained informed consent from the patient, patients voluntarily signing the informed consent form before study related actions including patient's acceptance of the scheduled program of clinical and radiographic analysis 2. The patient shall be at least 18 years of age, male or female and have passed cessation of growth 3. Patients asking for more than one dental implant and presenting one site with a healed site (class h1i, h2i; h3i, v1i, c1i, h1e, h2e, h3e, Cologne Classification of Alveolar Ridge Defects (CCARD) requiring a GBR procedure prior to implant placement. 4. The teeth at the implant site must have been extracted or lost at least 8 weeks before the date of bone augmentation (volumetrically healed site) Exclusion Criteria: Systemic exclusion criteria 1. Major systemic diseases (e.g. recent myocardial infarction, cerebrovascular accident or valvular prosthesis surgery, a poorly stabilized diabetes mellitus, severe hypertension, severe peripheral artery occlusive disease, malignancies, autoimmune diseases, or kidney diseases, untreated or uncontrolled periodontal disease, uncontrolled drug or alcohol abuse, uncontrolled psychiatric disorders) 2. Acute infectious diseases 3. Immunocompromised patients 4. Serious disturbances of bone metabolism and/or serious bone diseases of endocrine etiology 5. Due to judgement of the principal investigator: Medical conditions requiring prolonged use of steroids and/or on-going treatment with gluco- and mineralocorticoids and with agents affecting calcium metabolism (e.g. calcitonin), and/or anti-coagulative therapy 6. Previous or current use of antiresorptive medication (e.g. bisphosphonates) 7. Previous oral / maxillofacial radiotherapy 8. Heavy smoker (definition: \>10 cigarettes per day) 9. Currently pregnant or breastfeeding women 10. Health conditions, which do not permit the surgical treatment Local exclusion criteria 1. Acute local inflammation or untreated periodontitis 2. Insufficient oral hygiene 3. Regenerative periodontal treatment necessary adjacent to the planned study site of interest 4. Mucosal diseases or oral white or ulcerative lesions (e.g. lichen planus, leukoplakia) 5. History of head and neck irradiation therapy 6. Severe bruxism or clenching or other destructive habits 7. Previous socket preservation, GBR or guided tissue regeneration (GTR) treatment at the implant site 8. Infections in tissue and adjacent tissue of the planned implantation site 9. Known hypersensitivity to any of the trace elements 10. Edentulous cases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ridge augmentation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Copenhagen University Hospital, Department of Oral & Maxillofacial Surgery

    Copenhagen, 2100, Denmark

  • Medical University of Graz Department of Dental Medicine and Oral Health

    Graz, 8010, Austria

  • Studio Tabanella

    Roma, 00198, Italy

  • Studio medico odontoiatrico Papi Stp Srl

    Roma, 00176, Italy

  • University of Vienna, Department of Oral Surgery

    Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.